Summary
Vertex Pharmaceuticals reported a significant increase in total revenues for the nine months ended September 30, 2015, driven by the launch of ORKAMBI and strong performance from KALYDECO. While the company continues to incur substantial research and development expenses, particularly in its core cystic fibrosis program, the net loss attributable to Vertex narrowed significantly compared to the same period in the prior year. The company also made strategic advancements, including a significant collaboration with CRISPR Therapeutics for gene editing technologies and progress in its clinical trials for various CFTR modulator candidates. Key financial highlights include a substantial rise in product revenues, largely due to the initial sales of ORKAMBI post-FDA approval in July 2015. Despite increased operating costs, particularly in R&D and SG&A, the company's revenue growth outpaced expense growth, leading to a reduced net loss. Vertex maintains a strong liquidity position with over $1 billion in cash, cash equivalents, and marketable securities, providing a solid foundation for its ongoing development and commercialization efforts.
Financial Highlights
49 data points| Revenue | $309.82M |
| Cost of Revenue | $30.27M |
| Gross Profit | $279.55M |
| R&D Expenses | $246.28M |
| SG&A Expenses | $99.77M |
| Operating Expenses | $379.84M |
| Operating Income | -$70.03M |
| Net Income | -$95.15M |
| EPS (Basic) | $-0.39 |
| EPS (Diluted) | $-0.39 |
| Shares Outstanding (Basic) | 241.97M |
| Shares Outstanding (Diluted) | 241.97M |
Key Highlights
- 1Total revenues increased by 41% to $614.4 million for the nine months ended September 30, 2015, compared to $435.9 million in the prior year period.
- 2Product revenues more than doubled to $593.8 million for the nine months ended September 30, 2015, primarily driven by the launch of ORKAMBI and increased KALYDECO sales.
- 3Net loss attributable to Vertex narrowed to $482.6 million for the nine months ended September 30, 2015, a significant improvement from $561.9 million in the prior year period.
- 4Research and development expenses increased by 5% to $685.7 million for the nine months ended September 30, 2015, reflecting continued investment in its pipeline, particularly in cystic fibrosis.
- 5Sales, general, and administrative expenses increased by 23% to $280.0 million for the nine months ended September 30, 2015, supporting the commercialization of KALYDECO and ORKAMBI.
- 6The company reported $1.01 billion in cash, cash equivalents, and marketable securities as of September 30, 2015, indicating strong liquidity.
- 7Vertex entered into a significant strategic collaboration with CRISPR Therapeutics AG in October 2015 to develop gene editing treatments for genetic diseases, with an upfront payment of $75 million.